Myasthenia Gravis Drug Market 2034

Key Companies: Horizon Therapeutics, Amgen, Janssen Research & Development, LLC, Hoffmann-La Roche, Immunovant Sciences GmbH, Alexion, AstraZeneca Rare Disease, Regeneron Pharmaceuticals, Kyverna Therapeutics, Cartesian Therapeutics, Dianthus Therapeutics, Takeda, COUR Pharmaceuticals, HanAll Biopharma Co., Ltd. (South Korea), Chugai Pharmaceutical Co., Ltd. (Japan), Astellas Pharma Inc. (Japan), Ono Pharmaceutical Co., Ltd. (Japan), TWi Biotechnology, Inc. (Taiwan), OBI Pharma, Inc. (Taiwan), and others.

Market Summary: The Myasthenia Gravis market in the 7MM was valued at approximately USD 4,950 million in 2023, projected to grow substantially through 2034. In 2023, there were around 287,000 diagnosed prevalent cases across the 7MM, with 129,000 in the US, both expected to rise at a steady CAGR. Growth is driven by rising prevalence, diagnostic advances, and novel therapies from players like UCB Pharma, Argenx, and Horizon Therapeutics. Emerging treatments such as Nipocalimab, Batoclimab, and Descartes-08 will address therapeutic gaps in this rare autoimmune disorder. Asia, particularly Korea and Japan, is emerging as a key innovation hub, with FcRn inhibitors, plasma cell depletion, and B-cell targeting therapies shifting focus from symptom control to immune reset.

(Albany, USA) DelveInsight’s Myasthenia Gravis Market Insights Report covers current treatments, emerging drugs, market shares, and forecasted market size (2020–2034) across 7MM (US, EU-4, UK, Japan). Market dynamics will shift due to improved diagnostics, rising awareness, healthcare spending, and upcoming therapies.

Discover which therapies are expected to grab the major myasthenia gravis market share @ Myasthenia Gravis Market Report

Key Takeaways:

• The market is anticipated to grow at a significant CAGR by 2034, reaching substantial size from USD 4,950 million in 2023.
• US diagnosed cases: ~129,000 in 2023, expected to increase steadily.
• Leading companies are developing drugs like DAS-001, Amifampridine Phosphate, MuSK-CAART, Nipocalimab, Efgartigimod IV, Rozanolixizumab, ALXN1720, Batoclimab, Descartes-08, Zilucoplan (RA101495), and others. Asian players include HanAll's batoclimab (FcRn inhibitor, Phase 3, NCT05039190), Chugai's satralizumab (anti-IL-6R, Phase 2), Takeda's mezagitamab (anti-CD38, Phase 2), Astellas' immune modulation programs (early Phase 1/2), Ono's BTK inhibitors (early Phase 1/2), TWi's repurposed autoimmune therapies (early clinical), and OBI Pharma's antibody-based modulation (preclinical/Phase 1).

Recent Updates:

• April 2025: Phase 3 trial (NCT05737160) for Telitacicept (RC18) in gMG presented at AAN.
• March 2025: Immunovant shifts focus from batoclimab to IMVT-1402 after Phase III success (NCT05403541).
• March 2025: FDA approves expanded Soliris for pediatric gMG.
• January 2025: Cartesian secures FDA SPA for Phase 3 AURORA trial of Descartes-08.
• December 2024: Alexion study on eculizumab in pediatric gMG.
• October 2023: FDA approves ZILBRYSQ (zilucoplan) for gMG.
• September 2023: Recipharm partners with AHEAD THERAPEUTICS for MG therapy.
• April 2023: FDA approves Hizentra prefilled syringe.
• September 2022: Ultomiris approved in Europe for gMG.

Overview: Myasthenia Gravis (MG) is a chronic autoimmune disorder causing muscle weakness due to immune attacks on neuromuscular junctions. Symptoms include drooping eyelids, double vision, swallowing issues, and limb weakness. Diagnosis involves history, exams, EMG, and antibody tests.

Download the report to understand which factors are driving myasthenia gravis epidemiology trends @ Myasthenia Gravis Epidemiological Insights

Epidemiology Segmentation (2020–2034, 7MM):

• Total Generalized MG Diagnosed Prevalent Cases
• Gender-Specific Cases
• Antibodies-Specific Cases

Treatment: Involves acetylcholinesterase inhibitors (e.g., pyridostigmine), immunosuppressants (corticosteroids, azathioprine), IVIG, plasmapheresis, and thymectomy. Tailored plans are essential for management.

Learn more about the FDA-approved drugs for myasthenia gravis @ Drugs for Myasthenia Gravis Treatment

Key Therapies and Companies:

• Tolebrutinib: Sanofi
• Descartes-08: Cartesian Therapeutics
• Mezagitamab (TAK-079): Takeda
• DAS-001: DAS Therapeutics, Inc.
• Rozanolixizumab: UCB Biopharma
• Zilucoplan: UCB Biopharma
• Subcutaneous Efgartigimod: Argenx-Halozyme Therapeutics
• Uplizna (Inebilizumab): Horizon Therapeutics
• Enspryng (Satralizumab): Hoffmann-La Roche
• Nipocalimab: Janssen Research & Development, LLC
• Batoclimab: Immunovant Sciences GmbH / HanAll Biopharma

To know more about clinical trials, visit @ Myasthenia Gravis Treatment Drugs

Market Dynamics: Driven by rising cases, R&D, competition, and advocacy. Challenges include lack of cure, high R&D costs, regulations, and access barriers. Asian innovation, including FcRn inhibition (HanAll), plasma cell depletion (Takeda), B-cell signaling (Ono), cytokine blockade (Chugai), and immune modulation (Astellas, TWi, OBI), signals a shift to disease-modifying therapies.

Report Scope:

• Study Period: 2020–2034
• Coverage: 7MM (US, EU-4, UK, Japan)
• Key Companies: DAS-MG, Inc., Catalyst Pharmaceuticals, Inc., Cabaletta Bio, Janssen, Argenx, UCB Pharma, Alexion, Immunovant, Cartesian Therapeutics, Ra Pharmaceuticals, Inc., HanAll, Chugai, Takeda, Astellas, Ono, TWi Biotechnology, OBI Pharma, and others
• Key Therapies: DAS-001, Amifampridine Phosphate, MuSK-CAART, Nipocalimab, Efgartigimod IV, Rozanolixizumab, ALXN1720, Batoclimab, Descartes-08, Zilucoplan (RA101495), mezagitamab, satralizumab, and others
• Assessment: Marketed/emerging therapies, SWOT, entry strategies, unmet needs, KOL views, reimbursement.

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. 

Related report

Myasthenia Gravis - Pipeline Insight, 2026

DelveInsight’s, “Myasthenia Gravis Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Myasthenia Gravis pipeline landscape. The leading Myasthenia Gravis Companies developing therapies include - Argenx, Alexion AstraZeneca Rare Disease, Johnson & Johnson, Immunovant, Roivant Sciences, Cartesian Therapeutics, Novartis, Merck KGaA, and others.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: abhishek@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com